Luca Arcaini
Luca Arcaini
Department of Molecular Medicine, University of Pavia
Verified email at - Homepage
Cited by
Cited by
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
SP Treon, L Xu, G Yang, Y Zhou, X Liu, Y Cao, P Sheehy, RJ Manning, ...
New England Journal of Medicine 367 (9), 826-833, 2012
BRAF mutations in hairy-cell leukemia
E Tiacci, V Trifonov, G Schiavoni, A Holmes, W Kern, MP Martelli, ...
New England Journal of Medicine 364 (24), 2305-2315, 2011
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
L Malcovati, MGD Porta, C Pascutto, R Invernizzi, M Boni, E Travaglino, ...
Journal of Clinical Oncology 23 (30), 7594-7603, 2005
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project
M Federico, M Bellei, L Marcheselli, S Luminari, A Lopez-Guillermo, ...
Journal of Clinical Oncology 27 (27), 4555-4562, 2009
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation
G Fabbri, S Rasi, D Rossi, V Trifonov, H Khiabanian, J Ma, A Grunn, ...
Journal of Experimental Medicine 208 (7), 1389-1401, 2011
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ...
The Lancet 393 (10168), 229-240, 2019
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
F Passamonti, E Rumi, E Pungolino, L Malabarba, P Bertazzoni, ...
The American journal of medicine 117 (10), 755-761, 2004
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ...
The Lancet Haematology 7 (10), e737-e745, 2020
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and …
F Passamonti, E Rumi, D Pietra, C Elena, E Boveri, L Arcaini, E Roncoroni, ...
Leukemia 24 (9), 1574-1579, 2010
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele …
L Xu, ZR Hunter, G Yang, Y Zhou, Y Cao, X Liu, E Morra, A Trojani, ...
Blood, The Journal of the American Society of Hematology 121 (11), 2051-2058, 2013
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
D Rossi, V Spina, C Deambrogi, S Rasi, L Laurenti, K Stamatopoulos, ...
Blood, The Journal of the American Society of Hematology 117 (12), 3391-3401, 2011
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development
D Rossi, V Trifonov, M Fangazio, A Bruscaggin, S Rasi, V Spina, S Monti, ...
Journal of Experimental Medicine 209 (9), 1537-1551, 2012
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms
M Varettoni, L Arcaini, S Zibellini, E Boveri, S Rattotti, R Riboni, A Corso, ...
Blood, The Journal of the American Society of Hematology 121 (13), 2522-2528, 2013
ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
M Dreyling, C Thieblemont, A Gallamini, L Arcaini, E Campo, O Hermine, ...
Annals of Oncology 24 (4), 857-877, 2013
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative …
F Passamonti, E Rumi, D Pietra, MGD Porta, E Boveri, C Pascutto, ...
Blood 107 (9), 3676-3682, 2006
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
F Passamonti, E Rumi, L Arcaini, E Boveri, C Elena, D Pietra, S Boggi, ...
haematologica 93 (11), 1645-1651, 2008
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana …
M Federico, S Luminari, A Dondi, A Tucci, U Vitolo, L Rigacci, ...
Journal of Clinical Oncology 31 (12), 1506-1513, 2013
Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience
D Vallisa, P Bernuzzi, L Arcaini, S Sacchi, V Callea, R Marasca, ...
Journal of Clinical Oncology 23 (3), 468-473, 2005
Splenic marginal zone lymphoma: a prognostic model for clinical use
L Arcaini, M Lazzarino, N Colombo, S Burcheri, E Boveri, M Paulli, ...
Blood 107 (12), 4643-4649, 2006
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up✰
E Zucca, L Arcaini, C Buske, PW Johnson, M Ponzoni, M Raderer, ...
Annals of oncology 31 (1), 17-29, 2020
The system can't perform the operation now. Try again later.
Articles 1–20